Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer


Mangir N., Turkeri L.

ACTAS UROLOGICAS ESPANOLAS, vol.38, no.8, pp.515-522, 2014 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 8
  • Publication Date: 2014
  • Doi Number: 10.1016/j.acuro.2013.12.012
  • Title of Journal : ACTAS UROLOGICAS ESPANOLAS
  • Page Numbers: pp.515-522

Abstract

Introduction: Docetaxel administered every 3-weeks is the standart treatment of castration resistant prostate cancer (CRPC) but it is associated with dose limiting toxicities. We analyzed the efficacy and tolerability of 3- weekly and weekly docetaxel in a Turkish cohort of CRPC patients with a special emphasis on the elderly patients.